Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing.
It is a $11.2B technology company. Revenue grew 31.0% over the last year, it keeps 29¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 41.5× earnings — around the middle of its own history.
- Website
- novami.com
- Employees
- 1 612
- Sector
- Technology
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong growth, profitability, health, quality and moat; Valuation lags behind.
Valuation22
- P/E vs own history62th pct · 5/25
- FCF yield1.7% · 5/25
- P/S6.7x · 12/25
- EV/EBITDA41.4x · 0/25
Growth100
- Revenue CAGR20.6% · 25/25
- Net income CAGR29.2% · 25/25
- EPS CAGR ~5Y26.4% · 25/25
- Fwd implied growth43.4% · 25/25
Profitability90
- ROIC20.8% · 20/25
- ROE20.3% · 20/25
- Net margin29.4% · 25/25
- Operating margin25.3% · 25/25
Health93
- Altman Z7.67 · 25/25
- Current ratio1.55 · 18/25
- Interest coverageno interest expense · 25/25
- Net cash / debtNet cash · 25/25
Quality75
- Piotroski F5/9 · 15/25
- Beneish M-2.27 · 20/25
- FCF conversion73% · 15/25
- Margin stabilityσ 1.2% · 25/25
Moat100
- ROIC >12% years5/5 yrs · 25/25
- Median gross margin56.6% · 25/25
- FCF-positive years5/5 yrs · 25/25
- Worst-year net marginworst 22.4% · 25/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2026ProductNew obesity GLP-1 pills were launched, with patients getting their hands on them from Danish drugmaker Novo
- FY2025FinancialBest year on record$259M net income
- 2025AcquisitionNovo acquired Akero Therapeutics for $5.2 billion
- 2024AcquisitionParent company Novo Holdings agreed to acquire Catalent for $16.5 billion
- 2024MilestoneNovo reached a $604 billion market capitalization and became the 12th most valuable company in the world
- 2023MilestoneNovo's market capitalization exceeded the GDP of Denmark's domestic economy
- 2023AcquisitionNovo agreed to acquire the Montreal-headquartered pharmaceutical company, Inversago Pharma for $1…
- 2022AcquisitionNovo agreed to acquire Forma Therapeutics for $1.1 billion with the intent to expand its sickle…
- FY2021FinancialProfitable every year on record5 consecutive profitable years in our data
- FY2021FinancialPositive free cash flow every year since5-year streak
- 1991MilestoneNovo Nordisk Engineering (now NNE) demerged after working as in-house consultants at Novo for years, to…
- 1989AcquisitionThe corporation was created in 1989, through a merger of two Danish pharmaceutical companies
- 1985ProductThe company introduced the first insulin pen device called Novopen
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (55.6%)
- Strongly profitable — 29.4% net margin
- Revenue growing 31.0% year over year
- Strong cash conversion — FCF is 21.5% of revenue
- Net cash position after subtracting debt from cash
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+31.0% YoY
- Profitable — makes more than it spends$259M FY2025
- Profit growing — earnings are higher than last year+54.0% YoY
- Generates cash — cash left after running and investing$190M FY2025
- Debt under control — could handle its obligationsmore cash than debt
- Established company — not a micro-cap — lower blow-up risk$11.2B market cap
- Not printing shares — share count not ballooning — you keep your slice+9.2% shares over ~5y
- Proven track record — years of profitability behind it5/5 profitable years
- Financially stable — balance sheet not near distressAltman Z 7.7 — safe
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 41.5
Peer comparisonNova Ltd. vs 6 largest technology peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| NVMI this company | $11.2B | 41.5 | +31.0% | 29.4% | Strong |
| NVDA Nvidia Corp | $5.5T | 28.6 | +83.4% | 63.7% | Mixed |
| AAPL Apple Inc. | $4.9T | 38.1 | +14.2% | 27.6% | Strong |
| GOOGL Alphabet Inc. | $4.3T | 17.6 | +20.1% | 54.8% | Mixed |
| MSFT Microsoft Corp | $4.0T | 29.7 | +17.8% | 40.3% | Strong |
| SPCX Space Exploration Technologies Corp. | $2.1T | — | +33.2% | -34.0% | Strained |
| META Meta Platforms, Inc. | $1.8T | 26.9 | +27.7% | 29.8% | Mixed |
Head-to-head: NVMI vs NVDA · NVMI vs AAPL · NVMI vs GOOGL
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2021–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/NVMI
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of NVMI on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $352.47 · market cap $11.2B.